SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity.

Abstract

COI Statement

S. Rutella reports grants from Wugen outside the submitted work. A.D. Schimmer reports personal fees from Takeda Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, and Novartis and grants from Takeda Pharmaceuticals and Medivir outside the submitted work; a patent for DNT Cells for the Treatment of Leukemia pending; and being on the medical and scientific board of The Leukemia and Lymphoma Society of Canada. A.D. Schimmer is an inventor of DNT cell technology–related patents and intellectual properties for the treatment of AML. J. Lee reports a patent for US10517937 issued, a patent for US11020157 issued, a patent for US17/415957 pending, and a patent for US17/797630 pending. L. Zhang reports grants from Canadian Institutes of Health Research (grant #419699) and Canadian Cancer Society Impact Grant (grant #704121) during the conduct of the study; other support from Wyze Biotech Co. Ltd. outside the submitted work; a patent 4 issued, a patent 4 pending, and a patent 1 licensed; and having financial interests (e.g., holdings/shares) in Wyze Biotech Co. Ltd. and previously received research funding and consulting fee/honorarium from the company. No disclosures were reported by the other authors.

References:

• DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. . Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617–29.
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015;373:1136–52.
• Lee JB, Chen B, Vasic D, Law AD, Zhang L. Cellular immunotherapy for acute myeloid leukemia: how specific should it be? Blood Rev 2019;35:18–31.
• Sauerer T, Velázquez GF, Schmid C. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. Mol Cancer 2023;22:180.
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity 2020;52:17–35.